Cargando…

Case Report: Opportunities and Challenges of Immunotherapy in Heavily-Treated EGFR-Mutant Advanced Squamous Cell Lung Carcinoma After Progression on EGFR-TKIs and Chemotherapy

BACKGROUND: Epidermal growth factor receptor (EGFR) mutations have a low incidence in squamous cell lung cancer (SqCLC), and the clinical efficacy of EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutated SqCLC is far less than that in EGFR-mutated lung adenocarcinoma. The treatment strategy for pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Wei, Wang, Xin, Wang, Jie, Lin, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919069/
https://www.ncbi.nlm.nih.gov/pubmed/35296008
http://dx.doi.org/10.3389/fonc.2022.820408
_version_ 1784668872834547712
author Jin, Wei
Wang, Xin
Wang, Jie
Lin, Lin
author_facet Jin, Wei
Wang, Xin
Wang, Jie
Lin, Lin
author_sort Jin, Wei
collection PubMed
description BACKGROUND: Epidermal growth factor receptor (EGFR) mutations have a low incidence in squamous cell lung cancer (SqCLC), and the clinical efficacy of EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutated SqCLC is far less than that in EGFR-mutated lung adenocarcinoma. The treatment strategy for patients with EGFR-mutated non-small cell lung cancer who are refractory to EGFR TKIs has become a current dilemma and challenge. CASE PRESENTATION: A case of a 69-year-old male patient suffering from intermittent cough and hemoptysis was diagnosed with EGFR-mutated advanced SqCLC (stage cT2bN2M1). The patient was treated with camrelizumab alone after five courses of different systemic therapies and achieved a partial response, with an eminent progression-free survival of more than 24 months. Grade 1 to 2 reactive cutaneous capillary endothelial proliferation and mild pruritus were observed during the treatment. No other immune-related adverse events were observed. CONCLUSION: Monotherapy of immune-checkpoint inhibitors may be considered as a later-line option for EGFR-mutated advanced SqCLC patients with PD-L1 expression.
format Online
Article
Text
id pubmed-8919069
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89190692022-03-15 Case Report: Opportunities and Challenges of Immunotherapy in Heavily-Treated EGFR-Mutant Advanced Squamous Cell Lung Carcinoma After Progression on EGFR-TKIs and Chemotherapy Jin, Wei Wang, Xin Wang, Jie Lin, Lin Front Oncol Oncology BACKGROUND: Epidermal growth factor receptor (EGFR) mutations have a low incidence in squamous cell lung cancer (SqCLC), and the clinical efficacy of EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutated SqCLC is far less than that in EGFR-mutated lung adenocarcinoma. The treatment strategy for patients with EGFR-mutated non-small cell lung cancer who are refractory to EGFR TKIs has become a current dilemma and challenge. CASE PRESENTATION: A case of a 69-year-old male patient suffering from intermittent cough and hemoptysis was diagnosed with EGFR-mutated advanced SqCLC (stage cT2bN2M1). The patient was treated with camrelizumab alone after five courses of different systemic therapies and achieved a partial response, with an eminent progression-free survival of more than 24 months. Grade 1 to 2 reactive cutaneous capillary endothelial proliferation and mild pruritus were observed during the treatment. No other immune-related adverse events were observed. CONCLUSION: Monotherapy of immune-checkpoint inhibitors may be considered as a later-line option for EGFR-mutated advanced SqCLC patients with PD-L1 expression. Frontiers Media S.A. 2022-02-28 /pmc/articles/PMC8919069/ /pubmed/35296008 http://dx.doi.org/10.3389/fonc.2022.820408 Text en Copyright © 2022 Jin, Wang, Wang and Lin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Jin, Wei
Wang, Xin
Wang, Jie
Lin, Lin
Case Report: Opportunities and Challenges of Immunotherapy in Heavily-Treated EGFR-Mutant Advanced Squamous Cell Lung Carcinoma After Progression on EGFR-TKIs and Chemotherapy
title Case Report: Opportunities and Challenges of Immunotherapy in Heavily-Treated EGFR-Mutant Advanced Squamous Cell Lung Carcinoma After Progression on EGFR-TKIs and Chemotherapy
title_full Case Report: Opportunities and Challenges of Immunotherapy in Heavily-Treated EGFR-Mutant Advanced Squamous Cell Lung Carcinoma After Progression on EGFR-TKIs and Chemotherapy
title_fullStr Case Report: Opportunities and Challenges of Immunotherapy in Heavily-Treated EGFR-Mutant Advanced Squamous Cell Lung Carcinoma After Progression on EGFR-TKIs and Chemotherapy
title_full_unstemmed Case Report: Opportunities and Challenges of Immunotherapy in Heavily-Treated EGFR-Mutant Advanced Squamous Cell Lung Carcinoma After Progression on EGFR-TKIs and Chemotherapy
title_short Case Report: Opportunities and Challenges of Immunotherapy in Heavily-Treated EGFR-Mutant Advanced Squamous Cell Lung Carcinoma After Progression on EGFR-TKIs and Chemotherapy
title_sort case report: opportunities and challenges of immunotherapy in heavily-treated egfr-mutant advanced squamous cell lung carcinoma after progression on egfr-tkis and chemotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919069/
https://www.ncbi.nlm.nih.gov/pubmed/35296008
http://dx.doi.org/10.3389/fonc.2022.820408
work_keys_str_mv AT jinwei casereportopportunitiesandchallengesofimmunotherapyinheavilytreatedegfrmutantadvancedsquamouscelllungcarcinomaafterprogressiononegfrtkisandchemotherapy
AT wangxin casereportopportunitiesandchallengesofimmunotherapyinheavilytreatedegfrmutantadvancedsquamouscelllungcarcinomaafterprogressiononegfrtkisandchemotherapy
AT wangjie casereportopportunitiesandchallengesofimmunotherapyinheavilytreatedegfrmutantadvancedsquamouscelllungcarcinomaafterprogressiononegfrtkisandchemotherapy
AT linlin casereportopportunitiesandchallengesofimmunotherapyinheavilytreatedegfrmutantadvancedsquamouscelllungcarcinomaafterprogressiononegfrtkisandchemotherapy